ERNA Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -43.82%, SMA50 -68.79%, SMA200 -81.24%). The stock’s 14-day RSI is 25.75 (weak momentum), while the ATR of 0.09 points to moderate volatility. The stock remains hovering near 52-week lows, trading -93.98% below its high and over 11.11% above its low. Average 10-day trading volume of 19.19 thousand shares is below the 3-month average of 1.73 million, indicating normal recent market interest.

Ernexa Therapeutics Inc. generated EPS of -$4.75 over the past year. Five-year average earnings growth is 35.26%. Ernexa Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended May 11, 2026, missed forecasts by 256.41%. The prior quarter beat by 13.18%. Over the last six quarters, Apple has recorded several small beats. These include 37.5% in November 09, 2021.

Ernexa Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.53. This means the shares are trading above this model’s fair value.

Ernexa Therapeutics Inc. has 7.36 million shares outstanding. The public float is 3.16 million shares, elevated short interest at 1.11% of float. This equals 66.22 thousand shares. The short ratio is 0.81 days. Institutional investors hold 1.61% of the float. Insiders own 59.71%. BROADWOOD PARTNERS, L.P. holds 29.97 million shares, Cherington Charles has 4.00 million shares and Freebird Partners LP has 783.23 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Ernexa Therapeutics Inc. trades at a P/E ratio of -0.21, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.74 suggesting the stock is closer to book value. The P/FCF stands at -0.28, also above market averages.

Ernexa Therapeutics Inc. (NASDAQ:ERNA) closed at $6.73 USD, gaining $0.67 (11.06%) from the previous close of $6.06. The stock is currently mid-range between its 52-week high and low $3.18 and $71.50. With a market capitalization of about $2.11 million, Ernexa Therapeutics Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.51). Key stats such as the average daily volume over the past year has been around 1.67 million shares, trading with heavier-than-usual volume. Headquartered in Cambridge, MA, Ernexa Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sanjeev Luther, the company employs approximately 5 people and listed since August 29, 1991. Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs).

Our AI price prediction model suggests that Ernexa Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.94%, with price expected at $5.70 by July 28, 2026, within a range of $5.05 to $6.37 3-Month Outlook: Projected fall of -85.81%, reaching $0.86 by October 12, 2026, with a range of $0.00 to $3.41. 1-Year Outlook: Projected loss of -80.36%, with price at $1.19 by July 14, 2027, within a range of $0.00 to $13.60.

Ernexa Therapeutics Inc. (NASDAQ:ERNA) shares are flat 1.67% year-to-date currently trading near 52-week highs band. Short-term momentum has been flat over the last quarter, despite recent volatility. Valuation shows Ernexa Therapeutics Inc. trading at a premium to the broader market with a P/E of -0.21. Our AI forecast model points to short-term weakness (-5.94% over two weeks), a medium-term fall (-85.81% over three months), and a longer-term loss (-80.36% over one year), with expected trading ranges indicating moderate volatility.